Arbutus Biopharma Corp (ABUS) insider trading.
In Q3 2026, insiders at Arbutus Biopharma Corp reported 12 non-derivative transactions on 4 Forms 3, 4 and 5: 0 open-market purchases and 0 sales.
- Transactions
- 12
- Purchases (P)
- 0
- Sales (S)
- 0
- Net shares, P minus S
- 0
- Insiders
- 4
- Last filed
- 2026-09-23
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Beardsley Robert A | Director | 3 | 0 | 0 |
| Sawhney Roger | Director | 3 | 0 | 0 |
| Nguyen Tuan | Officer · Chief Financial Officer | 3 | 0 | 0 |
| Androski Lindsay | Director, Officer · President and CEO | 3 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-18 | Beardsley Robert A | F (D) | 99,057 | $5.07 | 32,276 | Form 4 |
| 2026-09-18 | Beardsley Robert A | M (A) | 52,533 | $3.2 | 52,533 | Form 4 |
| 2026-09-18 | Beardsley Robert A | M (A) | 78,800 | $4.24 | 131,333 | Form 4 |
| 2026-09-18 | Sawhney Roger | F (D) | 100,508 | $5.07 | 30,825 | Form 4 |
| 2026-09-18 | Sawhney Roger | M (A) | 78,800 | $4.24 | 131,333 | Form 4 |
| 2026-09-18 | Sawhney Roger | M (A) | 52,533 | $3.34 | 52,533 | Form 4 |
| 2026-09-18 | Nguyen Tuan | M (A) | 265,625 | $3.49 | 339,125 | Form 4 |
| 2026-09-18 | Nguyen Tuan | F (D) | 206,637 | $5.07 | 159,963 | Form 4 |
| 2026-09-18 | Nguyen Tuan | M (A) | 27,475 | $4.39 | 366,600 | Form 4 |
| 2026-09-18 | Androski Lindsay | M (A) | 116,408 | $3.2 | 144,408 | Form 4 |
| 2026-09-18 | Androski Lindsay | F (D) | 82,527 | $5.07 | 72,337 | Form 4 |
| 2026-09-18 | Androski Lindsay | M (A) | 10,456 | $4.39 | 154,864 | Form 4 |
Transaction codes in this quarter
Get ABUS insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1447028&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · ABUS company page · Arbutus Biopharma Corp on SEC.gov
Questions
Are insiders buying or selling Arbutus Biopharma Corp (ABUS)?
In Q3 2026, insiders at Arbutus Biopharma Corp reported 12 non-derivative transactions on 4 Forms 3, 4 and 5: 0 open-market purchases and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Arbutus Biopharma Corp insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/abus.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.